Creative medical technology announces positive top-line results for ovastem® pilot study

Three-year follow up results confirm significant efficacy and no serious adverse effects in patients receiving ovastem® procedure for treating primary ovarian insufficiency phoenix , july 28, 2022 /prnewswire/ -- creative medical technology holdings, inc. ("creative medical technology" or the "company") (nasdaq: celz), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced positive three-year follow up data for the company's ovastem® pilot study.  the data shows significant efficacy of the ovastem® procedure for the treatment of medical refractory primary ovarian insufficiency (poi) without any serious adverse effects and the successful birth of healthy babies.
CELZ Ratings Summary
CELZ Quant Ranking